BR112022008730A2 - Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo - Google Patents

Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo

Info

Publication number
BR112022008730A2
BR112022008730A2 BR112022008730A BR112022008730A BR112022008730A2 BR 112022008730 A2 BR112022008730 A2 BR 112022008730A2 BR 112022008730 A BR112022008730 A BR 112022008730A BR 112022008730 A BR112022008730 A BR 112022008730A BR 112022008730 A2 BR112022008730 A2 BR 112022008730A2
Authority
BR
Brazil
Prior art keywords
regulatory
antibody
specifically binds
cells
surface antigen
Prior art date
Application number
BR112022008730A
Other languages
English (en)
Inventor
Ho Kim Jung
Seok Kim Beom
Original Assignee
Good T Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Good T Cells Inc filed Critical Good T Cells Inc
Publication of BR112022008730A2 publication Critical patent/BR112022008730A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

EPÍTOPO DE ANTÍGENO DE SUPERFÍCIE DE CÉLULAS T REGULADORAS E UM ANTICORPO QUE SE LIGA ESPECIFICAMENTE AO MESMO A presente invenção se refere a um epítopo da proteína Lrig-1 (domínios semelhantes à imunoglobulina 1 e repetições ricas em leucina), que é um antígeno presente na superfície de uma célula T reguladora, e um anticorpo ou fragmento de ligação a antígeno que se liga especificamente ao mesmo.
BR112022008730A 2019-11-08 2020-11-09 Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo BR112022008730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190142251 2019-11-08
PCT/KR2020/015656 WO2021091359A1 (ko) 2019-11-08 2020-11-09 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체

Publications (1)

Publication Number Publication Date
BR112022008730A2 true BR112022008730A2 (pt) 2022-07-19

Family

ID=75848106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008730A BR112022008730A2 (pt) 2019-11-08 2020-11-09 Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo

Country Status (8)

Country Link
EP (1) EP4056586A4 (pt)
JP (1) JP2023500248A (pt)
KR (1) KR102488967B1 (pt)
CN (1) CN114929733A (pt)
AU (1) AU2020380072A1 (pt)
BR (1) BR112022008730A2 (pt)
CA (1) CA3156600A1 (pt)
WO (1) WO2021091359A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3882266A4 (en) * 2018-10-17 2022-07-27 Good T Cells, Inc. LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF
WO2023287212A1 (ko) * 2021-07-16 2023-01-19 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
WO2024155098A1 (ko) * 2023-01-17 2024-07-25 주식회사 굳티셀 조절 t 세포 표면 항원 및 이에 특이적으로 결합하는 항체

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180116925A (ko) * 2017-04-18 2018-10-26 주식회사 굳티셀 암 또는 면역 질환의 예방 또는 치료용 약학 조성물
AU2018256237A1 (en) * 2017-04-18 2019-12-05 Good T Cells, Inc. Binding molecule specific for Lrig-1 protein and use thereof
KR20180116924A (ko) * 2017-04-18 2018-10-26 주식회사 굳티셀 면역 세포 표면 단백질의 항원 결정기인 폴리펩티드
CN112040959A (zh) * 2018-02-23 2020-12-04 真和制药有限公司 通过阻断vista和其结合伴侣的相互作用治疗癌症
KR101959237B1 (ko) * 2018-02-26 2019-03-20 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
WO2019209078A1 (ko) * 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CA3156600A1 (en) 2021-05-14
KR20210056280A (ko) 2021-05-18
JP2023500248A (ja) 2023-01-05
EP4056586A4 (en) 2024-04-10
CN114929733A (zh) 2022-08-19
KR102488967B1 (ko) 2023-01-16
AU2020380072A1 (en) 2022-05-19
EP4056586A1 (en) 2022-09-14
WO2021091359A1 (ko) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112022008730A2 (pt) Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo
BR112018015670A2 (pt) construtos de anticorpo biespecíficos envolvendo células t
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
BR112018011100A2 (pt) anticorpo, composição, construto de ácido nucleico, vetor de expressão, célula hospedeira, método para tratamento de um indivíduo que tem um câncer, kit de partes, e, uso de um anticorpo ou de uma composição.
CO2020014773A2 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
BR112023003511A2 (pt) Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
CY1121169T1 (el) Αντισωμα που δεσμευει ενα γραμμικο επιτοπο ανθρωπινου ρ53 και διαγνωστικες εφαρμογες αυτου
BR112021023897A2 (pt) Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
BR112022001693A2 (pt) Construtos de proteína de ligação ao antígeno e usos dos mesmos
BR112017021026A2 (pt) novos métodos para seleção de epítopo.
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112019009765A2 (pt) anticorpo de ligação à anidrase carbônica e uso do mesmo
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112022011037A2 (pt) Anticorpos ddr1 novos e usos dos mesmos
BR112016019739A2 (pt) novo anticorpo de anti-presepsina